Celltech could not get the deal value it expected for its late-stage anti-inflammatory treatment--perhaps indicating a Big Pharma reluctance to pay the kinds of prices it has been paying. So UCB struck while it could. Led by new management it seized the opportunity to make what is a transforming move for the midsized European company-from undersized primary care group into a specialist, biopharma firm ranked alongside--indeed above--European biotech bellwether, Serono. If it works, the deal provides a model for other mid-sized European pharmas, looking for a way out of the primary care trap and, like UCB, to use mid-size advantages to power a sustainable long-term strategy.
By Roger Longman
Celltech Group PLC 's 2001 alliance with Pharmacia was one of those quintessential markers for the apparently ever frothier...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.
UK pharma faces a critical turning point as the Economic Crime and Corporate Transparency Act introduces the "Failure to Prevent Fraud" offense in September 2025, requiring companies to transform their approach to fraud prevention or face severe consequences.
Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.
